Log in

NASDAQ:NERV - Minerva Neurosciences Stock Price, Forecast & News

$8.36
-0.70 (-7.73 %)
(As of 01/19/2020 05:24 AM ET)
Add
Compare
Today's Range
$8.24
Now: $8.36▼
$9.23
50-Day Range
$5.59
MA: $7.04▼
$9.07
52-Week Range
$4.01
Now: $8.36▼
$9.23
Volume360,910 shs
Average Volume406,717 shs
Market Capitalization$326.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NERV
Previous Symbol
CUSIPN/A
CIK1598646
Webhttp://www.minervaneurosciences.com/
Phone617-600-7373

Debt

Debt-to-Equity RatioN/A
Current Ratio6.21
Quick Ratio6.21

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.32 per share
Price / Book3.60

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-50,170,000.00
Net MarginsN/A
Return on Equity-76.38%
Return on Assets-44.37%

Miscellaneous

Employees13
Outstanding Shares39,030,000
Market Cap$326.29 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:NERV Rates by TradingView

(Ad)


I call it my "Dividend Map", and I'll show you exactly where to find the safest companies that pay the highest yields. (HINT: Texas has 6 of these companies sending huge payouts that average 77%!). I'm willing to send you my Map... but only if you

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences Inc (NASDAQ:NERV) released its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. View Minerva Neurosciences' Earnings History.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Minerva Neurosciences.

What price target have analysts set for NERV?

4 equities research analysts have issued 12-month price targets for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Minerva Neurosciences' stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 142.2% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.

What is the consensus analysts' recommendation for Minerva Neurosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences.

What are Wall Street analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:
  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/29/2019)
  • 2. HC Wainwright analysts commented, "Valuation Our $22 price target for Minerva is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (5/31/2019)

Has Minerva Neurosciences been receiving favorable news coverage?

News articles about NERV stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Minerva Neurosciences.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 3,100,000 shares, a decrease of 16.9% from the December 15th total of 3,730,000 shares. Based on an average daily trading volume, of 428,000 shares, the days-to-cover ratio is currently 7.2 days. Currently, 9.6% of the shares of the stock are sold short. View Minerva Neurosciences' Current Options Chain.

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
  • Dr. Michael Davidson, Chief Medical Officer (Age 69)
  • Mr. Richard Russell, Pres (Age 55)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 44)

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $8.36.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $326.29 million. The biopharmaceutical company earns $-50,170,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.View Additional Information About Minerva Neurosciences.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is http://www.minervaneurosciences.com/.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]


MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  551
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Price to Earnings Ratio (PE) Basics
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel